Vnitr Lek 2025, 71(3):198-202 | DOI: 10.36290/vnl.2025.034
Updated procedures in the diagnosis and treatment of dyslipidemia
- 1 Klinika kardiologie, Laboratoř pro výzkum aterosklerózy, IKEM, Praha
- 2 OKB Fakultní nemocnice u sv. Anny, Brno
The aim of dyslipidemia treatment is to reduce cardiovascular (CV) risk as much as possible by lowering LDL-cholesterol (LDL-C) concentrations; in persons with higher triglyceride concentration (>1.7 mmol/l), especially non-HDL cholesterol (non-HDL-C). For each CV risk category there are recommended target values for LDL-C, apolipoprotein B and non-HDL-C. In recent years, there have been significant developments in the diagnosis and treatment of dyslipidemias. After almost 40 years since the introduction of statin therapy, new effective treatments are available, such as propotein convertase subtilisin kexin type 9 inhibitors (iPCSK9), bempedoic acid and others. The use of elimination methods (lipoprotein apheresis) is being considered more frequently and there is already initial experience with new drugs for the treatment of mixed dyslipidemia and lipoprotein(a) reduction. The cornerstone of treatment for all dyslipidemias is lifestyle modification; in the case of insufficient effect in reducing atherogenic lipoproteins in combination with pharmacotherapy. The first line drugs to control dyslipidemias are statins, often in combination with ezetimibe.
Keywords: dyslipidemia, new risk factors, atherogenic lipids, novel hypolipidemic therapy.
Accepted: April 28, 2025; Published: May 16, 2025 Show citation
References
- Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205; available from doi: 10.1016/j.atherosclerosis.2019.08.014.
Go to original source... 
Go to PubMed... - Bláha V, Bláha M, Lánská M, et al. LDL-aferéza: indikace, kontraindikace, klinický význam a vlastní zkuąenosti. Hypertenze a kardiovaskulární prevence. 2015;4(1):47-51.
- Lloyd-Jones, D, Morris, P. et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. JACC. 2022;1366-1418; available from https://doi.org/10.1016/j.jacc.2022.07.006. Go to original source... Go to PubMed...
- Ruscica M, Sirtori CR, Carugo S, et al. Bempedoic Acid: for Whom and When. Curr Atheroscler Rep. 2022;24(10):791-801; available from doi: 10.1007/s11883-022-01054-2. Go to original source... Go to PubMed...
- Vrablík M, Pi»ha J, Blaha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Athero-Rev. 2019;4(3):126-137; available from www.prolekare.cz/casopisy/athero-review/2019-3-14/stanovisko-vyboru-ceske-spolecnosti-pro-aterosklerozu-k-doporucenim-esc-eas-pro-diagnostiku-a-lecbu-dyslipidemii-z-roku-2019-115546. Go to original source...
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-3337; available from doi:10.1093/eurheartj/ehab484. Go to original source... Go to PubMed...
- Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681; available from doi:10.1016/S0140-6736(10)61350-5. Go to original source... Go to PubMed...